[Perspectives] Treatment toxicity in endometrial cancer: can we identify and manage it better?

We thank Dr Melanie Powell and Dr Remi Nout for taking the time to share their expertise on high-risk endometrial cancer during the March 17 –18 #radonc journal club on Twitter. During our conversation, we discussed the results of the PORTEC-3 trial, which confirms the findings of other randomised trials: a reduced risk of relapse by adding chemotherapy to radiotherapy, without improving overall survival. The risk of distant relapse wa s not significantly lower with chemotherapy, suggesting that a clear survival benefit might not be observed with a longer follow-up.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Perspectives Source Type: research